FDA Investigator Candice C Mandera

Candice C Mandera has conducted inspections on 98 sites in 3 countries as of 23 Jan 2006. See below for a list of the FDA enforcement documents resulting from those inspections.

Investigator Details

Number of Inspected Sites:
98
Last Inspection Date:
23 Jan 2006
Investigator Role:
FDA Investigator
Redica ID:
100001945
Countries of Inspections:
United States of America, Canada, United Kingdom of Great Britain and Northern Ireland
FDA Investigators that have inspected at least one site in common with Candice C Mandera:
Alan C Gion, Anthony F Lorenzo, Arindam Dasgupta, PhD, Billingsley, Brandon L Mariner, Brian R Yaun, Brooke K Higgins, Brooke K Seeman, Bryan J Love, Burnell M Henry, Candice J Cortes, Carol Rivera Lopez, PhD, Caroline Strasinger, Carrie L Doupnik, CDR Ileana Barreto Pettit, CDR Rochelle B Young, RPh, MSA, Chaltu Nwakijra, Charlean R Butler, Charles A Snipes, PhD, Christian D Lynch (CDL), Christine M Whitby, CSO, Christopher R Richardson, Chryste D Best, Clarice J Ahn, Cynthia A Harris, MD, RN, David A Oluwo, David L Chon, Dennis L Doupnik, Dianne H Milazzo, Dirk L Lincoln, Douglas A Campbell, Dr. Abhijit Raha, PhD, Dr. Gang Wang, PhD, Dr. Gopa Biswas, PhD, Dr. Sriram Subramaniam, PhD, Eleanor M Felton, Elise A Murphy, Emest F Bizjak, Emmanuel A Dimaano, Jr, Eric L Dong, BS, Erin L Mcfiren, Esaw, Gale L Glinecki, George Pyramides, Gerald B Seaborn, Jr, Gerald D Bromley, Jr, Gerald Mierle, Gifford Whitehurst, Jr, Heath A Gerber, Hugh M Mcclure, II, Huixia Zhang, Jacqueline A O'shaughnessy, PhD, Jacqueline Mdiaz Albertini, James M Simpson, James W Leonette, Jessica L Pressley, Jingbo Xiao, Joey C West, John A Kadavil, PhD, John Dan, Johnson, Jonathan W Chapman, Jose R Hernandez, Justin A Boyd, Kailee R Mason, Karen A Briggs, Kenneth Nieves, Lawrence Harmon, Jr, Lawrence J Stringer, LCDR Debra Emerson, LCDR Matthew R Mcnew, MPH, REHS/RS, LCDR Wilfred A Darang, Leon L Crawley, Lisa B Orr, Lori S Lawless, LT Luis O Rodriguez, LT Melanie M Mayor, USPHS, Luella J Rossi, Luis A Dasta, Lynette P Salisbury, Marcus A Ray, Martin K Yau, PhD, Marya F Ricks, Meghan Murphy, Melissa J Garcia, Merideth K Rose, Michael F Skelly, PhD, Mihaly S Ligmond, Nathaniel R Esaw, Nawab A Siddiqui, Nebil A Oumer, Olaide Akinmade, Parul M Patel, Qin Xu, Rachel C Harrington, Raymond W Niles, Robert Durkin, Robert J Maffei, Robin Levis, PhD, Ronald T Nowalk, Ruark Lanham, Sam H Haidar, PhD, Sam Pepe, Samuel H Chan, PharmD, Sean Y Kassim, PhD, Sena G Dissmeyer, Sherry L Secrist, BLT DO, Sierra M Shockley, Srinivas R Chennamaneni, PhD, Stephanie L Shapley, Stephanie Mangigian, MS/OSH, RN, Stephen C Eason, Steven J Thurber, Steven P Donald, Susan M Jackson, Swati Verma, Tajah L Blackburn, Tamal K Chakraborti, PhD, Tamara N Champion, Temar Q Williams, Thai D Truong, Thomas J Hudson, Thomas R Withers, Tiki J Dixon, Walter L Fava, William D Bassett, Jr, William H Linkroum, William L Bargo, Xikui Chen (nmi), PhD, Yih Chain Huang, PhD, Zi Qiang Gu

Candice C Mandera's Documents

Publish Date Document Type Title
December, 2005 FDA 483 Response PPD Development, L.P. - Form 483R, 2005-12-22
December, 2002 EIR Robert S. Call, M.D. - EIR, 2002-12-13
September, 2000 FDA 483 Frederick G. Hayden, M.D. - Form 483, 2000-09-13
August, 2002 EIR Boehringer Ingelheim Chemicals, Inc. - EIR, 2002-08-08
May, 2000 FDA 483 Shiffman, Mitchell L MD - Form 483, 2000-05-12
February, 2000 FDA 483 Response Euclid Systems Corporation - Form 483R, 2000-03-01
August, 2002 FDA 483 Boehringer Ingelheim Chemicals, Inc. - Form 483, 2002-08-08
December, 2001 FDA 483 PPD Development, L.P. - Form 483, 2001-12-19
December, 2005 FDA 483 PPD Development, L.P. - Form 483, 2005-12-15
April, 2002 FDA 483 Response Harry D Bear MD - Form 483R, 2002-10-18
August, 2000 EIR Frederick G. Hayden, M.D. - EIR, 2000-08-11
January, 2000 FDA 483 Response Boehringer Ingelheim Chemicals, Inc. - Form 483R, 2000-02-07
August, 2002 EIR Central Admixture Pharmacy Services Inc - EIR, 2002-08-21
October, 2000 FDA 483 Doxtater, Gary M. DVM - Form 483, 2000-10-19
January, 2000 FDA 483 Boehringer Ingelheim Chemicals, Inc. - Form 483, 2000-01-07
September, 2003 EIR PPD Development, L.P. - EIR, 2003-09-12
August, 2002 EIR EMINENT Services Corporation - EIR, 2002-08-29
November, 2002 EIR Stuart Adler - EIR, 2002-11-12
September, 2000 EIR Frederick G. Hayden, M.D. - EIR, 2000-09-13
February, 2001 FDA 483 Frank M Ludwig MD - Form 483, 2001-02-13
August, 2003 FDA 483 Jeffrey L McLeod MD - Form 483, 2003-08-06
May, 2002 EIR PPD Development, L.P. - EIR, 2002-05-17
December, 2001 EIR PPD Development, L.P. - EIR, 2001-12-19
May, 2000 EIR Shiffman, Mitchell L MD - EIR, 2000-05-12
August, 2003 FDA 483 Stephen H Caldwell MD - Form 483, 2003-08-21
July, 2004 FDA 483 PPD Development, L.P. - Form 483, 2004-07-21
August, 2002 EIR Scientific Laboratories, Inc. - EIR, 2002-08-21
April, 2002 EIR Harry D Bear MD - EIR, 2002-04-29
January, 2000 EIR Boehringer Ingelheim Chemicals, Inc. - EIR, 2000-01-07
September, 2003 EIR PPD Development, L.P. - EIR, 2003-09-05
August, 2000 FDA 483 Response Frederick G. Hayden, M.D. - Form 483R, 2000-08-21
October, 2001 EIR Susan Kornstein MD - EIR, 2001-10-19
May, 2003 EIR John H. Gilliam, MD - EIR, 2003-05-27
July, 2004 EIR PPD Development, L.P. - EIR, 2004-07-21
February, 2002 EIR Merck Sharp & Dohme LLC - EIR, 2002-02-06
September, 2003 FDA 483 PPD Development, L.P. - Form 483, 2003-09-05
February, 2001 EIR Frank M Ludwig MD - EIR, 2001-02-13
December, 2005 EIR PPD Development, L.P. - EIR, 2005-12-15
April, 2003 FDA 483 Lauraine M Stewart MD - Form 483, 2003-04-28
July, 2004 FDA 483 Response PPD Development, L.P. - Form 483R, 2004-08-16
February, 2000 EIR Euclid Systems Corporation - EIR, 2000-02-16
August, 2000 FDA 483 Frederick G. Hayden, M.D. - Form 483, 2000-08-11
May, 2002 FDA 483 PPD Development, L.P. - Form 483, 2002-05-17
April, 2004 FDA 483 New River Pharmaceuticals Inc - Form 483, 2004-04-27
June, 2001 FDA 483 Fareva Richmond, Inc. - Form 483, 2001-06-22

Experience Redica Systems’ NEW investigator profiles and dashboards

Redica Systems customers get access to over 1,400 FDA Investigator profiles, containing powerful analysis like:

  • Total inspections conducted
  • 483 rate
  • OAI rate
  • Warning Letter rate
  • Inspections by Industry, Scope, and Inspection Reason
  • And much more

Investigator Profiles are not sold as on-demand documents. If you’d like to see one, fill out the form below to connect with our Sales Team and get it in your inbox as little as 24 hours.

FDA Investigator Profile Icon

Talk to sales to access our investigator profiles

Loading...

Investigator Profiles Are Just the Tip of the Iceberg

Becoming a Redica Systems customer not only provides you with unlimited access to profiles similar to the one above for every current and former FDA Investigator, but also grants you access to:

Inspection Intelligence

  • Pre-Approval Inspection (PAI) trends
  • The ability to filter nearly any FDA enforcement action by GxP labels like GMP, GCP, etc.
  • Latest 483s: see what the trends are across all FDA Investigators
  • CFR Heatmap: Citations aggregated by Subpart by Year

Vendor Intelligence

  • Full inspection histories for your vendors down to the specific site level
  • All of the functionality mentioned above but isolated to just your vendors

Regulatory Intelligence

  • Zero in on the trends for a specific agency/regulator (ex. FDA, MHRA, EMA, Health Canada)
  • All the latest "Signals" from agencies around the world, segmented by Country, Type (ex. Guidance, Decree...), Category (ex. Rules/Regulations/Guidance, News, Reports...), Theme (ex. Cell and Gene Therapy, AI...), and more